R Squared Ltd Purchases Shares of 860 Guardant Health, Inc. (NASDAQ:GH)

R Squared Ltd purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 860 shares of the company’s stock, valued at approximately $26,000.

Other large investors have also recently added to or reduced their stakes in the company. JNBA Financial Advisors bought a new stake in Guardant Health during the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC bought a new position in shares of Guardant Health in the 3rd quarter worth $34,000. Nisa Investment Advisors LLC boosted its position in shares of Guardant Health by 168.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock worth $79,000 after purchasing an additional 2,153 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Guardant Health by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after purchasing an additional 796 shares during the last quarter. Finally, KBC Group NV raised its stake in Guardant Health by 63.6% during the 4th quarter. KBC Group NV now owns 5,658 shares of the company’s stock worth $173,000 after buying an additional 2,200 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $47.17 on Wednesday. The company has a fifty day moving average of $37.47 and a 200-day moving average of $30.36. The company has a market capitalization of $5.83 billion, a PE ratio of -11.12 and a beta of 1.32. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $50.89.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. During the same quarter last year, the company posted ($0.73) earnings per share. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. On average, equities analysts forecast that Guardant Health, Inc. will post -3.43 EPS for the current fiscal year.

Analysts Set New Price Targets

GH has been the subject of several analyst reports. Guggenheim restated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 22nd. Barclays began coverage on Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. The Goldman Sachs Group lifted their price target on shares of Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Finally, Sanford C. Bernstein dropped their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Sixteen analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health has an average rating of “Buy” and an average target price of $42.63.

Insider Buying and Selling

In other news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. This trade represents a 46.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,548 shares of company stock valued at $179,782 over the last 90 days. 5.50% of the stock is owned by insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.